{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-036866","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2026-09-17T13:27:26+00:00","discovered_at":"2026-09-17T13:28:23.158914+00:00","generated_at":"2026-09-17T13:28:38.989731+00:00","sec_items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Lisata closes Marea reverse merger; $225M PIPE financing","bullets":["Merger closed Sept 17, 2026; Marea stockholders get 1,793,129 LSTA shares + 211,365 Series C preferred (convertible to common).","$225M PIPE: 150,867.995 Series C preferred shares sold to investors; expected close Sept 18, 2026.","Post-deal ownership: LSTA legacy holders ~2.39%, Marea holders ~59.54%, PIPE investors ~38.07% (on conversion).","Ted Love (ex-GBT CEO) joins board; Josh Lehrer (Marea CEO) named President & COO; Mazzo stays CEO.","180-day lock-up on insider shares; stockholder vote needed for Series C conversion and change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-036866","json":"https://secwatch.observer/filing/0001140361-26-036866.json","markdown":"https://secwatch.observer/filing/0001140361-26-036866.md","text":"https://secwatch.observer/filing/0001140361-26-036866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/ef20082158_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-17T13:28:38.989731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5aee5e15a2","claim":"David J. Mazzo resigned as President at LISATA THERAPEUTICS, INC..","evidence_excerpt":"Immediately prior to such appointment, David J. Mazzo, Ph.D. resigned solely from the office of President, but he retained his position as Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"7be5af1509","claim":"Josh Lehrer was appointed as President and Chief Operating Officer at LISATA THERAPEUTICS, INC..","evidence_excerpt":"In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Josh Lehrer, M.D., M.Phil., FACC was appointed as the President and Chief Operating Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"fdcb0d2572","claim":"Ted W. Love was appointed as Director at LISATA THERAPEUTICS, INC..","evidence_excerpt":"In accordance with the Merger Agreement, on September 17, 2026 , effective immediately after the First Effective Time, Ted W. Love, M.D. was appointed to the Board as a director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000114036126036866/0001140361-26-036866-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}